Scarica l'app Stockscreener
45.45
1.73%
-0.80
Pre-mercato:
45.35
-0.10
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$46.25
Aprire:
$44.9612
Volume 24 ore:
1.12M
Relative Volume:
0.52
Capitalizzazione di mercato:
$5.63B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-10.72
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
-4.94%
1M Prestazione:
-6.39%
6M Prestazione:
-6.48%
1 anno Prestazione:
+39.08%
Intervallo 1D:
$44.75
$45.59
Intervallo di 1 settimana:
$44.75
$49.30
Portata 52W:
$20.14
$53.42
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
45.45 | 5.73B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
466.71 | 161.42B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.89 | 135.99B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
540.68 | 42.78B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.47 | 33.01B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
194.24 | 31.85B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
What analysts say about Guardant Health Inc. stockFree Stock Selection - Autocar Professional
What drives Guardant Health Inc. stock priceDynamic growth stocks - Autocar Professional
10 Best Mid Cap Pharma Stocks to Buy - Insider Monkey
Colonoscopies are no fun. These at-home colon cancer screenings offer a shortcut. - Business Insider
Guardant Health Inc. Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
Is Guardant Health Inc. a good long term investmentFree Consultation - jammulinksnews.com
Cathie Wood’s ARK ETFs shift focus, buying NVIDIA and selling GUARDANT - Investing.com
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences - Benzinga
Guardant Health (GH): director Tariq Musa sells $5591 in stock By Investing.com - Investing.com South Africa
Guardant Health (GH): director Tariq Musa sells $5591 in stock - Investing.com
Guardant Health Director Sells 142 Shares at $48.2 Per Share on 2025-07-17. - AInvest
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Lung Cancer Diagnostics Market Expansion Driven by Liquid - openPR.com
(GH) Technical Data - news.stocktradersdaily.com
User - FinancialContent
Evercore ISI Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - BioSpace
Guardant Health stock price target maintained at $60 by Evercore ISI - Investing.com Canada
What makes Guardant Health Inc. stock price move sharplyFree Stock Portfolio Optimization - beatles.ru
Press Release: Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - 富途牛牛
Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations' - Law360
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know - MSN
US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case - Reuters
East Bay company looks to bring cancer insights to rheumatoid arthritisSan Francisco Business Times - The Business Journals
Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGRRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Guardant Health Insider Sold Shares Worth $5,087,630, According to a Recent SEC Filing - MarketScreener
The 5 Most Interesting Analyst Questions From Guardant Health’s Q1 Earnings Call - Yahoo Finance
Is GH's Q1 2025 forecast achievable? - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer - The Lancet
Guardant Health’s Colorectal Cancer Screening Test Earns Another Honor - Medical Product Outsourcing
Precision Medicine: The Future of Healthcare? Companies Like Tempus AI, Guardant Health, and Exact Sciences Are Pioneering the Way - AInvest
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Benzinga
Guardant Health gets Breakthrough Device Designation from FDA for cancer detection test - Mugglehead Magazine
Medical Services Stock Near A Buy Point, It Just Needs A Boost - Investor's Business Daily
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.84%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):